Artigo de periodico

Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure (2019)

• Authors:
  • Ponikowski, Piotr
  • Kirwan, Bridget-Anne
  • Anker, Stefan D.
  • Dorobantu, Maria
  • Drozdz, Jaroslaw
  • Fabien, Vincent
  • Filippatos, Gerasimos
  • Haboubi, Teba
  • Keren, Andre
  • Nicolau, José Carlos
• Autor USP: NICOLAU, JOSÉ CARLOS - FM
• Unidade: FM
• DOI: 10.1002/ejhf.1710
• Subjects: INSUFICIÊNCIA CARDÍACA; DOENÇAS NUTRICIONAIS E METABÓLICAS; FERRO; COMPOSTOS INORGÂNICOS; HOSPITALIZAÇÃO; ENSAIO CLÍNICO CONTROLADO RANDOMIZADO; RESULTADO DE TRATAMENTO
• Agências de fomento:
  • Ionis
  • Mars and Heartware
  • Cardiorentis
  • Astra ZenecaAstraZeneca
  • Zoll
  • SJM/Abbott
  • RocheRoche Holding
  • PfizerPfizer
  • CSL Behring
  • Novo NordiskNovo Nordisk
  • AstraZenca
  • AmgenAmgen
  • Vifor
  • Janssen Research Development
  • Sanofi
  • NovartisNovartis
  • ServierServier
  • Boehringer IngelheimBoehringer Ingelheim
  • BayerBayer AG
  • Vifor Int
• Language: Inglês
• Imprenta:
  • Publisher place: Hoboken
  • Date published: 2019
• Source:
  • Título do periódico: European journal of heart failure
  • ISSN: 1388-9842
  • Volume/Número/Paginação/Ano: v. 21, n. 12, p. 1651-1658, 2019

Informações sobre o DOI: 10.1002/ejhf.1710 (Fonte: oaDOI API)
• Este periódico é de assinatura
• Este artigo é de acesso aberto
• URL de acesso aberto
• Cor do Acesso Aberto: green
• Licença: other-oa

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  PONIKOWSKI, Piotr et al. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European journal of heart failure, v. 21, n. 12, p. 1651-1658, 2019Tradução . . Disponível em: https://doi.org/10.1002/ejhf.1710. Acesso em: 19 abr. 2024.

• APA

  Ponikowski, P., Kirwan, B. -A., Anker, S. D., Dorobantu, M., Drozdz, J., Fabien, V., et al. (2019). Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European journal of heart failure, 21( 12), 1651-1658. doi:10.1002/ejhf.1710

• NLM

  Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Nicolau JC. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure [Internet]. European journal of heart failure. 2019 ; 21( 12): 1651-1658.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1002/ejhf.1710

• Vancouver

  Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Nicolau JC. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure [Internet]. European journal of heart failure. 2019 ; 21( 12): 1651-1658.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1002/ejhf.1710

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
• Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
• Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
• Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
• Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
• Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
• Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
• Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
• Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
• Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study